P3 Health Partners Inc. (PIIIW) — SEC Filings
P3 Health Partners Inc. (PIIIW) — 39 SEC filings. Latest: 8-K (Nov 28, 2025). Includes 20 8-K, 6 10-Q, 5 SC 13G/A.
View P3 Health Partners Inc. on SEC EDGAR
Overview
P3 Health Partners Inc. (PIIIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 28, 2025: P3 Health Partners Inc. filed an 8-K on November 21, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly Foresight Acquisition Corp., is incorporated in Delaware and has its principal executive offices in Henderson, Nevada.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 5 bearish, 34 neutral. The dominant filing sentiment for P3 Health Partners Inc. is neutral.
Filing Type Overview
P3 Health Partners Inc. (PIIIW) has filed 20 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 SC 13G, 2 SC 13D/A, 5 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of PIIIW's 32 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $345.253M |
| Net Income | -$69.461M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $37.714M |
| Operating Margin | N/A |
| Total Assets | $683.564M |
| Total Debt | $252.795M |
Key Executives
- Dr. David M. Smith
- Mr. Robert L. Johnson
- Ms. Sarah Chen
- Dr. Michael L. Riff
- Taylor Leavitt
- Dr. David L. Smith
- Mr. David M. Smith
- BEN LEVINE
- STEFAN RENOLD
Industry Context
P3 Health Partners operates within the highly competitive and rapidly evolving healthcare sector, particularly focusing on value-based care models for Medicare Advantage and other managed care populations. The industry is characterized by increasing regulatory scrutiny, pressure on reimbursement rates, and a shift towards integrated care delivery to manage costs and improve patient outcomes. Competitors range from large national insurers to regional health systems and specialized physician groups.
Top Tags
corporate-action (7) · material-agreement (5) · healthcare (5) · financial-reporting (4) · 10-Q (4) · 8-K (4) · shareholder-vote (3) · corporate-governance (3) · sec-filing (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $69.461M | Improved from $102.850M in Q3 2024, but still a significant loss. |
| Total Operating Revenue (Q3 2025) | $345.253M | Decreased from $362.124M in Q3 2024, indicating revenue decline. |
| Total Operating Expense (Q3 2025) | $389.476M | Reduced from $469.114M in Q3 2024, contributing to narrowed loss. |
| Premium Deficiency Reserve (Q3 2025) | $23.736M | A positive adjustment, contrasting with an $18.168M expense in Q3 2024. |
| Accumulated Deficit (Sept 30, 2025) | $575.622M | Increased from $503.193M at Dec 31, 2024, highlighting ongoing losses. |
| Total Assets (Sept 30, 2025) | $683.564M | Decreased from $783.420M at Dec 31, 2024. |
| Total Liabilities (Sept 30, 2025) | $664.636M | Increased from $633.891M at Dec 31, 2024, nearing total assets. |
| Class A Common Stock Shares Outstanding (Nov 3, 2025) | 3,286,465 | Reflects shares after 1-for-50 reverse stock split. |
| Commission File Number | 001-40033 | Identifies the company's SEC filing record. |
| I.R.S. Employer Identification No. | 85-2992794 | Company's tax identification number. |
| Net Loss (Q2 2025) | $43.665M | Increased from $28.774M in Q2 2024, a 51.7% increase. |
| Net Loss (YTD June 30, 2025) | $87.911M | Increased from $78.380M in YTD June 30, 2024, a 12.2% increase. |
| Total Operating Revenue (Q2 2025) | $355.788M | Decreased from $379.157M in Q2 2024, a 6.1% decline. |
| Capitated Revenue (Q2 2025) | $351.724M | Decreased from $374.306M in Q2 2024. |
| Net Cash Used in Operating Activities (YTD June 30, 2025) | $50.099M | Indicates significant cash burn, worsening from $30.272M in YTD June 30, 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for P3 Health Partners Inc. (PIIIW)?
P3 Health Partners Inc. has 39 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PIIIW filings?
Across 39 filings, the sentiment breakdown is: 5 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find P3 Health Partners Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all P3 Health Partners Inc. (PIIIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for P3 Health Partners Inc.?
Key financial highlights from P3 Health Partners Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PIIIW?
The investment thesis for PIIIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at P3 Health Partners Inc.?
Key executives identified across P3 Health Partners Inc.'s filings include Dr. David M. Smith, Mr. Robert L. Johnson, Ms. Sarah Chen, Dr. Michael L. Riff, Taylor Leavitt and 4 others.
What are the main risk factors for P3 Health Partners Inc. stock?
Of PIIIW's 32 assessed filings, 4 were flagged high-risk, 18 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from P3 Health Partners Inc.?
Forward guidance and predictions for P3 Health Partners Inc. are extracted from SEC filings as they are enriched.